Hormonal
Obesity significantly increases the risk of cardiovascular disease, heart failure, and cerebrovascular disease, even in individuals classified as 'metabolically healthy'.
If you have obesity, your risk for heart disease and heart failure is significantly higher than someone with a normal weight, even if your blood pressure and cholesterol are currently normal. You should prioritize cardiovascular health monitoring and weight management strategies to mitigate this elevated risk.
A cohort study using prospectively collected data from 'The Health Improvement Network' (THIN) database demonstrated that some individuals with obesity who are classified as 'metabolically healthy' still face an elevated risk for coronary heart disease (49% increased risk), cerebrovascular disease (7% increased risk), and heart failure (96% increased risk), compared to normal-weight individuals without metabolic risk factors.
Why this rating
Supported by a large prospective cohort study (THIN database) and multiple mechanistic studies.
Source
Obesity and Its Comorbidities: Current Treatment Options, Emerging Biological Mechanisms, Future Perspectives and Challenges
Lihua Wang et al. · Diabetes Metabolic Syndrome and Obesity · 2025
DOI 10.2147/dmso.s540103
More from this paper
- Metabolic bariatric surgery (MBS) is the most effective intervention for achieving long-term and sustained weight loss and can reverse certain metabolic defects like insulin resistance by altering gut hormone secretion.Strong
- Obesity increases the risk of various cancers, including breast, endometrial, ovarian, kidney, thyroid, and gastrointestinal cancers, through mechanisms involving chronic inflammation, adipokine secretion, and epigenetic dysregulation.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →